Cargando…
Innovative prolonged-release oral alkalising formulation allowing sustained urine pH increase with twice daily administration: randomised trial in healthy adults
A multi-particulate fixed-dose combination product, consisting of a combination of two alkalising salts formulated as prolonged-release granules, ADV7103, was developed to obtain a sustained and prolonged alkalising effect. The specific release of both types of granules was shown in vitro through th...
Autores principales: | Guittet, C., Roussel-Maupetit, C., Manso-Silván, M. A., Guillaumin, F., Vandenhende, F., Granier, L. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434908/ https://www.ncbi.nlm.nih.gov/pubmed/32811843 http://dx.doi.org/10.1038/s41598-020-70549-2 |
Ejemplares similares
-
An innovative ethosuximide granule formulation designed for pediatric use: Comparative pharmacokinetics, safety, tolerability, and palatability profile versus reference syrup
por: Diezi, Léonore, et al.
Publicado: (2022) -
Efficacy of oral midazolam for minimal and moderate sedation in pediatric patients: A systematic review
por: Manso, Maria A., et al.
Publicado: (2019) -
Once– versus twice–daily tacrolimus: are the formulations equivalent?
por: Ciszek, Michał
Publicado: (2013) -
Alkalising agents in urinary tract infections: theoretical contraindications, interactions and synergy
por: Kavanagh, Oisín N.
Publicado: (2022) -
Improved growth of a child with primary distal renal tubular acidosis after switching from a conventional alkalizing treatment to a new prolonged-release formulation containing potassium citrate and potassium bicarbonate: lessons for the clinical nephrologist
por: Boyer, Olivia, et al.
Publicado: (2022)